CONTEXT: Zinc transporter 8 (ZnT8) is a newly discovered islet autoantigen in human type 1A diabetes (T1D). OBJECTIVE: The objective was to document changes in ZnT8 autoantibody (ZnT8A) titer and prevalence after onset of disease in relationship to 65 kDa glutamate decarboxylase antibody (GADA) and islet cell antigen antibody (IA2A). DESIGN/PATIENTS: Autoantibody radioimmunoprecipitation assays were performed on sera from three groups: 21 individuals monitored every 3 months from diagnosis for 2.5 yr; 61 individuals monitored at six monthly intervals for 5-12 yr; and a cross-sectional study of 424 patients with T1D of 20-57 yr duration. Circulating C-peptide was determined as an index of residual β-cell function. RESULTS: ZnT8A titers declined exponentially from clinical onset of T1D with a t(1/2) ranging from 26 to 530 wk, similar to C-peptide (23-300 wk). Life-table analysis of antibody prevalence to 12 yr indicated that ZnT8A measured with either Arg325 or Trp325 probes persisted for a shorter interval than IA2A. Although prevalence of ZnT8A, IA2A, and GADA were comparable at disease onset (70.4 vs. 73.4 vs. 64%), only 6.7% of individuals remained ZnT8A positive after 25 yr compared with 19.5% for IA2A and 25.9% for GADA. Titers of ZnT8A and IA2A in seropositive individuals decreased progressively, whereas GADA remained elevated consistent with periodic reactivation of GADA humoral autoimmunity. CONCLUSIONS: ZnT8 humoral autoreactivity declines rapidly in the first years after disease onset and is less persistent than IA2A or GADA in the longer term. ZnT8A determination may be a useful measure of therapeutic efficacy in the context of immune-based clinical interventions.
CONTEXT: Zinc transporter 8 (ZnT8) is a newly discovered islet autoantigen in human type 1A diabetes (T1D). OBJECTIVE: The objective was to document changes in ZnT8 autoantibody (ZnT8A) titer and prevalence after onset of disease in relationship to 65 kDa glutamate decarboxylase antibody (GADA) and islet cell antigen antibody (IA2A). DESIGN/PATIENTS: Autoantibody radioimmunoprecipitation assays were performed on sera from three groups: 21 individuals monitored every 3 months from diagnosis for 2.5 yr; 61 individuals monitored at six monthly intervals for 5-12 yr; and a cross-sectional study of 424 patients with T1D of 20-57 yr duration. Circulating C-peptide was determined as an index of residual β-cell function. RESULTS:ZnT8A titers declined exponentially from clinical onset of T1D with a t(1/2) ranging from 26 to 530 wk, similar to C-peptide (23-300 wk). Life-table analysis of antibody prevalence to 12 yr indicated that ZnT8A measured with either Arg325 or Trp325 probes persisted for a shorter interval than IA2A. Although prevalence of ZnT8A, IA2A, and GADA were comparable at disease onset (70.4 vs. 73.4 vs. 64%), only 6.7% of individuals remained ZnT8A positive after 25 yr compared with 19.5% for IA2A and 25.9% for GADA. Titers of ZnT8A and IA2A in seropositive individuals decreased progressively, whereas GADA remained elevated consistent with periodic reactivation of GADA humoral autoimmunity. CONCLUSIONS:ZnT8 humoral autoreactivity declines rapidly in the first years after disease onset and is less persistent than IA2A or GADA in the longer term. ZnT8A determination may be a useful measure of therapeutic efficacy in the context of immune-based clinical interventions.
Authors: E Kawasaki; M Uga; K Nakamura; G Kuriya; T Satoh; K Fujishima; M Ozaki; N Abiru; H Yamasaki; J M Wenzlau; H W Davidson; J C Hutton; K Eguchi Journal: Diabetologia Date: 2008-10-11 Impact factor: 10.122
Authors: R Jensen; L Gilliam; C Torn; M Landin-Olsson; J Palmer; K Akesson; I Kockum; B Lernmark; A F Karlsson; K F Lynch; N Breslow; A Lernmark; G Sundkvist Journal: Diabet Med Date: 2007-08-24 Impact factor: 4.359
Authors: Shilpa Oak; Lisa K Gilliam; Mona Landin-Olsson; Carina Törn; Ingrid Kockum; Christina R Pennington; Merrill J Rowley; Michael R Christie; J Paul Banga; Christiane S Hampe Journal: Proc Natl Acad Sci U S A Date: 2008-03-26 Impact factor: 11.205
Authors: Johnny Ludvigsson; Maria Faresjö; Maria Hjorth; Stina Axelsson; Mikael Chéramy; Mikael Pihl; Outi Vaarala; Gun Forsander; Sten Ivarsson; Calle Johansson; Agne Lindh; Nils-Osten Nilsson; Jan Aman; Eva Ortqvist; Peter Zerhouni; Rosaura Casas Journal: N Engl J Med Date: 2008-10-08 Impact factor: 91.245
Authors: Janet M Wenzlau; Kirstine Juhl; Liping Yu; Ong Moua; Suparna A Sarkar; Peter Gottlieb; Marian Rewers; George S Eisenbarth; Jan Jensen; Howard W Davidson; John C Hutton Journal: Proc Natl Acad Sci U S A Date: 2007-10-17 Impact factor: 11.205
Authors: Janet M Wenzlau; Yu Liu; Liping Yu; Ong Moua; Kimberly T Fowler; Sampathkumar Rangasamy; Jay Walters; George S Eisenbarth; Howard W Davidson; John C Hutton Journal: Diabetes Date: 2008-06-30 Impact factor: 9.461
Authors: David T Broome; Kevin M Pantalone; Sangeeta R Kashyap; Louis H Philipson Journal: J Clin Endocrinol Metab Date: 2021-01-01 Impact factor: 5.958
Authors: William Donelan; Hai Wang; Shi-Wu Li; David Pittman; Yi Li; Shuhong Han; Yu Sun; Christopher Carter; Mark Atkinson; Westley Reeves; William E Winter; Li-Jun Yang Journal: Int J Clin Exp Pathol Date: 2013-05-15
Authors: Anna E Long; Kathleen M Gillespie; Rachel J Aitken; Julia C Goode; Polly J Bingley; Alistair J K Williams Journal: Diabetes Date: 2013-02-08 Impact factor: 9.461